GRAIL, Inc. Common Stock

$18.63+8.19%(+$1.41)
TickerSpark Score

Not enough financial coverage to compute a composite score for GRALV. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.

Momentum80
52-Week Range56% of range
Low $12.51
Current $18.63
High $23.36

Companygrail.com

GRAIL, LLC, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests.

CEO
Robert P. Ragusa
HQ
Menlo Park, CA, US

Price Chart

+18.08% · this period
$20.32$16.99$13.66Jun 12Jul 02Jul 22

Performance & Tape

52W High
$23.36
52W Low
$12.51
50D MA
$15.94
200D MA
$15.94
Beta
0.00
Avg Volume
2.37M

Get TickerSpark's AI analysis on GRALV

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Our GRALV Coverage

We haven't published any research on GRALV yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate GRALV Report →

Similar Companies